🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guadalajara
Clinical trial register · Mexico

Clinical Trials in Guadalajara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1580 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
1580
Studies in scope
all four open statuses
714
Recruiting now
open to new participants
249
Lead sponsors
across recruiting studies
Top sites
Guadalajara 40 Mexico City 33 Chihuahua City 32 Monterrey 28 Mérida 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company40 AstraZeneca35 Merck Sharp & Dohme LLC30 Hoffmann-La Roche24 Bristol-Myers Squibb18 Clear sponsor filter
Site location
Guadalajara40 Mexico City33 Chihuahua City32 Monterrey28 Mérida14
All 46 locations
Target enrolment
to

Trials with a site in Guadalajara

40 of 1580 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
DrugsDulaglutide·Orforglipron
Eli Lilly and Company
Phase 3
170
Ciudad Madero, Guadalajara, Monterrey
2026-09
Not yet open
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 3
150
Guadalajara, León, Monterrey, Querétaro
2026-09
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Ciudad Madero, Culiacán, Guadalajara, Mexico City, Mérida, Monterrey, San Nicolás de los Garza, Tlalpan
2026-08-26
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Ciudad de Tijuana, Cuernavaca, Guadalajara, Irapuato, Mexico City, Mérida, Tlalnepantla, Torreón
2026-05-06
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Chihuahua City, Ciudad de Tijuana, Guadalajara, Irapuato, Mexico City, Monterrey, Querétaro
2026-03-26
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Guadalajara, Huixquilucan, Mexicali, Mexico City, Monterrey
2026-02-10
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756Depressive Disorder, Major
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,000
Chihuahua City, Guadalajara, Mazatlán, Mexico City, Mérida, Morelia, Veracruz
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Guadalajara, Mérida, Monterrey
2025-12-15
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Actopan, Ciudad Madero, Cuernavaca, Culiacán, Durango, Guadalajara, Hermosillo, León
2025-12-01
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
Chihuahua City, Guadalajara, Mazatlán, Mexico City, Mérida, Morelia
2025-11-24
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Chihuahua City, Durango, Guadajalara, Guadalajara, Mexico City, San Pedro Garza García, Tijuana, Tlalnepantla
2025-11-10
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Aguascalientes, Chihuahua City, Durango, Guadalajara, Mérida, Morelia, Querétaro, Veracruz
2025-10-22
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Chihuahua City, Cuauhtémoc, Cuernavaca, Guadalajara, Metepec, Mexico City, Mérida, Monterrey
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Actopan, Aguascalientes, Ciudad Madero, Cuernavaca, Culiacán, Guadalajara, Hermosillo, León
2025-09-02
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Aguascalientes, Chihuahua City, Ciudad Madero, Durango, Guadajalara, Guadalajara, Juriquilla, Mexico City
2025-06-26
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Aguascalientes, Chihuahua City, Ciudad Madero, Durango, Guadajalara, Guadalajara, Juriquilla, Mexico City
2025-06-26
Active, closed
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
465
Chihuahua City, Guadalajara, Mexico City, Monterrey, Puebla City, Tampico
2025-05-12
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
Chihuahua City, Guadalajara, Hacienda de Las Palmas, Monterrey, Puebla City, Tampico
2025-04-25
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Culiacán, Guadalajara, Juriquilla, León, Mexico City, Puebla City
2024-11-18
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
Aguascalientes, Guadalajara, Monterrey, Puebla City
2024-06-03
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Actopan, Aguascalientes, Ciudad Madero, Cuauhtémoc, Ciudad de México, Cuernavaca, Durango, Guadalajara, León
2024-04-30
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
DrugRetatrutide
Eli Lilly and Company
Phase 3
320
Chihuahua City, Guadalajara, Mérida, Veracruz
2024-03-15
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Aguascalientes, Chihuahua City, Cuernavaca, Culiacán, Durango, Guadalajara, Hermosillo, León
2024-03-05
Active, closed
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Diabetes Mellitus, Type 2
DrugsRetatrutide·Semaglutide
Eli Lilly and Company
Phase 3
1,250
Guadalajara, Mexico City, Cuernavaca, Monterrey, Chihuahua City, Veracruz
2024-02-21
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Guadalajara, Juriquilla, León, Mexico City, Monterrey, Oaxaca City, Puebla City, San Pedro Garza García
2023-12-21
Active, closed
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252Type 2 Diabetes, Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 2
414
Tijuana, Guadalajara, Cuauhtémoc, Ciudad de México, Mexico City, Monterrey, Ciudad Madero
2023-09-21
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Aguascalientes, Chihuahua City, Ciudad Madero, Cuauhtémoc, Cuernavaca, Culiacán, Durango, Guadalajara
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Chihuahua City, Ciudad Madero, Guadalajara, León, Mexico City, Monterrey, Oaxaca City, Puebla City
2022-10-04
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
DrugTirzepatide
Eli Lilly and Company
Phase 4
780
Guadalajara, Monterrey, Chihuahua City
2022-08-01
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone
Eli Lilly and Company
Phase 3
925
Guadalajara, Mexico City, Monterrey, Culiacán, Chihuahua City, Oaxaca City
2022-04-14
Active, closed
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567Breast Neoplasm, Neoplasm Metastasis
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
368
Mexicali, Tijuana, Guadalajara, Monterrey, San Luis Potosí City
2022-03-11
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
DrugSelpercatinib
Eli Lilly and Company
Phase 3
152
Guadalajara, Mexico City, Monterrey
2021-12-20
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326Chronic Migraine
DrugGalcanezumab
Eli Lilly and Company
Phase 3
312
Aguascalientes, Chihuahua City, Guadalajara, Mexico City, Morelia
2020-11-25
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944Non-Small Cell Lung Cancer
DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
261
Mexico City, Guadalajara, San Luis Potosí City
2020-02-17
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088396Systemic Juvenile Idiopathic Arthritis
DrugsBaricitinib·Tocilizumab
Eli Lilly and Company
Phase 3
58
Chihuahua City, Durango, Guadalajara, México, Monterrey
2020-02-12
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
DrugBaricitinib
Eli Lilly and Company
Phase 3
190
Chihuahua City, Durango, Guadalajara, México, Monterrey
2019-04-05
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286Episodic Migraine
DrugGalcanezumab
Eli Lilly and Company
Phase 3
533
Aguascalientes, Chihuahua City, Guadalajara, Morelia
2018-03-14
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Torreón, Mexico City, Guadalajara, Monterrey, Juchitán de Zaragoza, Culiacán, Toluca, Mérida
2017-07-12
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
DrugsAnastrozole·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 3
493
Torreón, México, León, Guadalajara, Mexico City, Cuernavaca, Juchitán de Zaragoza, Colinas Del Cimatario
2014-11-06
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
Tijuana, León, Guadalajara, Mexico City, Monterrey
2014-07-22
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-mexico/city/guadalajara

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,580 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Guadalajara that also match the filters currently applied.

How many clinical trials are recruiting in Guadalajara?

18 of the 40 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guadalajara), 40 studies
PhaseStudiesRecruitingShare
Phase 3331382.5%
Phase 26515%
Phase 4102.5%

Most active sponsors

Lead sponsors with the most studies (Guadalajara)
Lead sponsorStudiesRecruiting
Eli Lilly and Company4018
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.